Novo Nordisk is gradually ending production of human insulin pens, the drugmaker told Reuters, as it spends billions to ramp ...

EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...

Correspondent Jon Wertheim revisits 60 Minutes' coverage of former mobile giant Nokia and discusses potential risks for the ...

while in the United States all doses of Ozempic are currently available. Nevertheless, the shortage is still a strong hint of the extremely high demand and Novo Nordisk might be able to grow ...

Both Ozempic and Wegovy are forms of semaglutide, a GLP-1 agonist drug manufactured by Novo Nordisk ... demand for semaglutide within the United States exceeds the available supply.

“Honestly, I’m quite alarmed by what we see in the U.S. now,” Novo Nordisk President and CEO Lars Fruergaard ... the demand ...

COPENHAGEN (Reuters) - Novo Nordisk is lifting curbs on prescriptions of its weight-loss drug Wegovy in the United States and is increasing supply in that market, its CEO said on Wednesday.

The Stoxx Europe 600 Index swelled 1.5% to 517.07. Related NewsInflation Rate YoY for Oct in United States is 2.6%, higher ...

“For example, your company charges $969 in the United States for one month of Ozempic but just $155 in Canada and just $59 in Germany,” Sanders wrote. While Novo Nordisk pushes for a ban on ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

After decades as a political outsider, Sanders has used his committee chairmanships and proximity to the White House to ...

Belgium and the United States - onto Novo Nordisk for $11 billion. The sites will then by fully used by Novo Nordisk for ...